How have RDHL shares performed in 2023?

RedHill Biopharma's stock was trading at $5.6120 on January 1st, 2023. Since then, RDHL stock has decreased by 59.4% and is now trading at $2.28. View the best growth stocks for 2023 here .

Are investors shorting RedHill Biopharma?

RedHill Biopharma saw a drop in short interest in November. As of November 15th, there was short interest totaling 29,100 shares, a drop of 90.1% from the October 31st total of 293,600 shares. Based on an average trading volume of 4,720,000 shares, the short-interest ratio is presently 0.0 days. Approximately 0.3% of the shares of the company are short sold. View RedHill Biopharma's Short Interest .

When is RedHill Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, December 5th 2023. View our RDHL earnings forecast .

How were RedHill Biopharma's earnings last quarter?

RedHill Biopharma Ltd. (NASDAQ:RDHL) announced its quarterly earnings data on Tuesday, November, 30th. The biotechnology company reported ($20.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($19.20) by $0.80. The biotechnology company earned $21.61 million during the quarter, compared to analyst estimates of $23.41 million. RedHill Biopharma had a net margin of 354.95% and a negative trailing twelve-month return on equity of 328.99%. During the same quarter in the previous year, the business posted ($20.00) earnings per share.

When did RedHill Biopharma's stock split?

Shares of RedHill Biopharma reverse split before market open on Thursday, March 23rd 2023. The 1-40 reverse split was announced on Thursday, March 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of RedHill Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN) , Sorrento Therapeutics (SRNE) , Sangamo Therapeutics (SGMO) , Verastem (VSTM) , Amarin (AMRN) , Aralez Pharmaceuticals (ARLZ) , Inovio Pharmaceuticals (INO) , Tesla (TSLA) , Gilead Sciences (GILD) and NVIDIA (NVDA) .

Who are RedHill Biopharma's major shareholders?

RedHill Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (6.53%), Sabby Management LLC (5.74%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of RedHill Biopharma?

Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

RedHill Biopharma Stock Price, News & Analysis (NASDAQ:RDHL)

$2.28

+1.28 (+128.00%)

(As of 11/28/2023 ET)

Compare

Today's Range: $1.17
▼
$2.79
50-Day Range: $0.31
▼
$2.28
52-Week Range: $0.26
▼
$15.20

Volume: 152.67 million shs
Average Volume: 9.92 million shs
Market Capitalization: $25.24 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About RedHill Biopharma Stock (NASDAQ:RDHL)

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

RDHL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RDHL Stock News Headlines

November 27, 2023 | investorplace.com

5 Investors Betting Big on RedHill Biopharma (RDHL) Stock

November 27, 2023 | msn.com

Why Is Gastrointestinal Disease Focused-RedHill Biopharma Stock Higher Over 100% Today?

November 29, 2023 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.

November 27, 2023 | markets.businessinsider.com

RedHill's Talicia Granted 5-year Market Exclusivity By FDA

November 27, 2023 | finance.yahoo.com

RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034

November 22, 2023 | americanbankingnews.com

RedHill Biopharma (NASDAQ:RDHL) Now Covered by Analysts at StockNews.com

November 22, 2023 | finance.yahoo.com

RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market

October 19, 2023 | benzinga.com

The Street Reports: Guide to Penny Stocks Look Now! CLNV, ARAV, RDHL, ATHX, EPAZ

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

October 3, 2023 | msn.com

Israel-Based Penny Stock RedHill Biopharma Is Trading Higher Today - Here's Why?

October 3, 2023 | finance.yahoo.com

RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study

September 5, 2023 | finance.yahoo.com

RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)

August 17, 2023 | finance.yahoo.com

RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights

July 31, 2023 | finance.yahoo.com

RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA

July 25, 2023 | finance.yahoo.com

RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant Exercise

July 21, 2023 | benzinga.com

What's Going On With RedHill Biopharma Stock Today

July 21, 2023 | finance.yahoo.com

RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds

July 21, 2023 | finance.yahoo.com

RedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development

July 6, 2023 | technews.tmcnet.com

Phil and RedHill Biopharma Partner to Increase Access to Talicia®

June 12, 2023 | finanznachrichten.de

RedHill Biopharma Ltd.: RedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights

June 12, 2023 | finance.yahoo.com

RedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights

May 24, 2023 | bizjournals.com

Raleigh drug developer trims R&D pipeline, shifts resources

May 22, 2023 | finance.yahoo.com

RedHill Provides R&D Update

May 15, 2023 | finance.yahoo.com

RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

May 9, 2023 | finance.yahoo.com

RedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease Week

May 1, 2023 | finance.yahoo.com

RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting

April 28, 2023 | finanznachrichten.de

RedHill Biopharma Ltd.: RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights

See More Headlines

Receive RDHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/30/2021
Today: 11/29/2023
Next Earnings (Estimated): 12/05/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RDHL
CUSIP: N/A
CIK: 1553846
Web: www.redhillbio.com
Phone: 972-3541-3131
Fax: 972-3541-3144
Employees: 113
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-71,670,000.00
Net Margins: 354.95%
Pretax Margin: -9.10%
Return on Equity: -328.99%
Return on Assets: 71.39%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.96
Quick Ratio: 0.78

Sales & Book Value

Annual Sales: $61.80 million
Price / Sales: 0.41
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($16.41) per share
Price / Book: -0.14

Miscellaneous

Outstanding Shares: 11,070,000
Free Float: 10,317,000
Market Cap: $25.24 million
Optionable: Optionable
Beta: 2.14

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Dror Ben-Asher (Age 57)
Co-Founder, CEO & Director
Comp: $734.59k
Mr. Gilead Raday MPhil (Age 48)
MSc, Chief Operating Officer
Comp: $445.38k
Mr. Adi Frish (Age 53)
Chief Corporate & Business Development Officer
Comp: $419.5k
Mr. Rick D. Scruggs (Age 63)
Chief Commercial Officer, President of RedHill Biopharma Inc. & Director
Comp: $607.05k
Mr. Razi Ingber (Age 39)
Chief Financial Officer
Ms. Alexandra Okmian
Senior Business Development & Investor Relations Manager
Dr. Reza Fathi Ph.D. (Age 68)
Senior Vice President of Research & Development
Comp: $299.29k
Mr. Guy Goldberg (Age 47)
Chief Business Officer
Comp: $338.13k
Ms. Patricia Anderson B.Sc. RAC
Senior Vice President of Regulatory Affairs

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

RDHL Stock Analysis - Frequently Asked Questions

How have RDHL shares performed in 2023?: RedHill Biopharma's stock was trading at $5.6120 on January 1st, 2023. Since then, RDHL stock has decreased by 59.4% and is now trading at $2.28.
View the best growth stocks for 2023 here.
Are investors shorting RedHill Biopharma?: RedHill Biopharma saw a drop in short interest in November. As of November 15th, there was short interest totaling 29,100 shares, a drop of 90.1% from the October 31st total of 293,600 shares. Based on an average trading volume of 4,720,000 shares, the short-interest ratio is presently 0.0 days. Approximately 0.3% of the shares of the company are short sold.
View RedHill Biopharma's Short Interest.
When is RedHill Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, December 5th 2023.
View our RDHL earnings forecast.
How were RedHill Biopharma's earnings last quarter?: RedHill Biopharma Ltd. (NASDAQ:RDHL) announced its quarterly earnings data on Tuesday, November, 30th. The biotechnology company reported ($20.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($19.20) by $0.80. The biotechnology company earned $21.61 million during the quarter, compared to analyst estimates of $23.41 million. RedHill Biopharma had a net margin of 354.95% and a negative trailing twelve-month return on equity of 328.99%. During the same quarter in the previous year, the business posted ($20.00) earnings per share.

When did RedHill Biopharma's stock split?: Shares of RedHill Biopharma reverse split before market open on Thursday, March 23rd 2023. The 1-40 reverse split was announced on Thursday, March 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
What other stocks do shareholders of RedHill Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA).
Who are RedHill Biopharma's major shareholders?: RedHill Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (6.53%), Sabby Management LLC (5.74%) and Concourse Financial Group Securities Inc. (0.00%).
How do I buy shares of RedHill Biopharma?: Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:RDHL) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial